MedImmune reports earnings

MEDI reported a second quarter loss per share of $0.12, excluding charges associated with ending its deal with Wyeth (WYE) for FluMist. The Street had expected a loss of $0.17. In the second quarter of 2003, MEDI posted EPS of $0.05, which reflects one-time milestone payments for the approval of FluMist in June 2003 and for exceeding $100 million in ex-U.S. sales of Synagis in one season.

Revenues were $94 million in the second quarter, down from $113 million in the same period last year, which included the one-time milestones. Sales were up 13% quarter over quarter to $90.7 million from $80.6 million. Second quarter sales of Synagis palivizumab to prevent pediatric RSV infection were up 10% to $56 million. ...